Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6922361 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL9590900 | 0.75 | — | — | |
| Hydrochloric Acid SCHEMBL11402703 | 0.73 | — | — | |
| Hydrochloric Acid SCHEMBL4469626 | 0.71 | — | — | |
| SCHEMBL7877257 | 0.71 | — | — | |
| SCHEMBL24183388 | 0.71 | — | — | |
| SCHEMBL22649335 | 0.71 | — | — | |
| SCHEMBL24293016 | 0.71 | — | — | |
| Hydrochloric Acid SCHEMBL11840877 | 0.69 | — | — | |
| Hydrochloric Acid SCHEMBL8972600 | 0.69 | MME (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250129091-A1 | THIENOPYRROLOTRIAZINE COMPOUNDS, THEIR PREPARATION AND THEIR THERAPEUTIC USE | SANOFI (FR) | 2025-04-24 | — | — | US | disclosed |
| EP-4482841-A1 | THIENOPYRROLOTRIAZINE COMPOUNDS, THEIR PREPARATION AND THEIR THERAPEUTIC USE | Sanofi (FR) | 2025-01-01 | — | — | EP | disclosed |
| US-12168012-B2 | NLRP3 inflammasome inhibitors | NOVARTIS AG (CH) | 2024-12-17 | — | — | US | disclosed |
| EP-3827008-B1 | NLRP3 INFLAMMASOME INHIBITORS | NOVARTIS AG (CH) | 2024-07-31 | — | — | EP | disclosed |
| CN-112424207-B | NLRP3 inflammatory corpuscle inhibitor | 诺华股份有限公司 | 2024-03-19 | — | — | CN | disclosed |
| WO-2023156643-A1 | THIENOPYRROLOTRIAZINE COMPOUNDS, THEIR PREPARATION AND THEIR THERAPEUTIC USE | SANOFI (FR) | 2023-08-24 | — | — | WO | disclosed |
| CN-114478537-A | Cyclic amide-fused ring compound and medical use thereof | 上海拓界生物医药科技有限公司 | 2022-05-13 | — | — | CN | disclosed |
| US-20210308140-A1 | NLRP3 INFLAMMASOME INHIBITORS | NOVARTIS AG (CH) | 2021-10-07 | — | — | US | disclosed |
| EP-3827008-A1 | NLRP3 INFLAMMASOME INHIBITORS | Novartis AG (CH) | 2021-06-02 | — | — | EP | disclosed |
| CN-112424207-A | NLRP3 inflammasome inhibitor | 诺华股份有限公司 | 2021-02-26 | — | — | CN | disclosed |
| US-6403774-B1 | WATER SOLUBLE POLYMERIZATION INITIATOR. | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2002-06-11 | — | — | US | disclosed |
| EP-1195376-A1 | Azoamidine compounds and their use as polymerization initiators | Wako Pure Chemical Industies, Ltd. (JP) | 2002-04-10 | — | — | EP | disclosed |
| US-20020028469-A1 | Method of defining genus of chemical compound and method of designing molecules | BURCH RONALD M (US) | 2002-03-07 | — | — | US | disclosed |
| EP-1045850-A4 | PURINE COMPOUNDS HAVING PDE IV INHIBITORY ACTIVITY AND METHODS OF SYNTHESIS | EURO CELTIQUE SA (LU) | 2001-10-31 | — | — | EP | disclosed |
| US-6211367-B1 | REACTING AN 2-IMIDAZOLINE COMPOUND WITH A BENZALDEHYDE; REDUCTION | EURO-CELTIQUE, S.A. (LU) | 2001-04-03 | — | — | US | disclosed |
| EP-1045850-A1 | PURINE COMPOUNDS HAVING PDE IV INHIBITORY ACTIVITY AND METHODS OF SYNTHESIS | Euro-Celtique S.A. (LU) | 2000-10-25 | — | — | EP | disclosed |
| WO-1999029694-A1 | PURINE COMPOUNDS HAVING PDE IV INHIBITORY ACTIVITY AND METHODS OF SYNTHESIS | EURO-CELTIQUE, S.A. (LU) | 1999-06-17 | — | — | WO | disclosed |
| EP-0648769-A1 | 12-Hetero-substituted 6,11-ethano-6,11-dihydrobenzo[b] quinolizium salts and compositions and method of use thereof | STERLING WINTHROP INC. (US) | 1995-04-19 | — | — | EP | disclosed |
| US-5380729-A | Treatment or prevention of neurodegenerative disorders or neurotoxic injuries | STERLING WINTHROP INC. (US) | 1995-01-10 | — | — | US | disclosed |
| US-4163848-A | Process for the production of 2-alkyl- or cycloalkyl-4-methyl-6-hydroxypyrimidines | CIBA-GEIGY CORPORATION (US) | 1979-08-07 | — | — | US | disclosed |